

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 20, 2017

STRATA  
SKIN SCIENCES

**STRATA SKIN SCIENCES, INC.**  
(Exact Name of Registrant Specified in Charter)

**Delaware**  
(State or Other  
Jurisdiction of  
Incorporation)

**000-51481**  
(Commission File  
Number)

**13-3986004**  
(I.R.S. Employer  
Identification No.)

**100 Lakeside Drive, Suite 100, Horsham, Pennsylvania**  
(Address of Principal Executive Offices)

**19044**  
(Zip Code)

Registrant's telephone number, including area code: **215-619-3200**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events.**

On December 20, 2017, Strata Skin Sciences, Inc., a Delaware corporation (the "Company"), announced that Ms. LuAnn Via had been unanimously appointed as its Chairperson of its Board of Directors. Ms. Via is a current Board member and Chair of the Company's Compensation Committee. The Board made the appointment after Jeffrey O'Donnell, Sr. informed the Board that, because of the growing needs of his other commitments, he could no longer devote the time and energy as required by the position of Chairman. Mr. O'Donnell will remain a member of the Company's Board of Directors.

Mr. O'Donnell's consulting agreement with the Company will terminate at the end of its current term on December 31, 2017.

On December 20, 2017, the Company issued a press release announcing the appointment of Ms. Via as Chairperson. A copy of the press release is furnished herewith as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be deemed to be "filed":

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release by the Company, dated December 20, 2017.

**Exhibit Index**

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#">Press Release by the Company, dated December 20, 2017.</a>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**STRATA SKIN SCIENCES, INC.**

By: /s/ Frank McCaney  
**Frank McCaney**  
**President and Chief Executive Officer**

Date: December 20, 2017

## STRATA Skin Sciences Announces Appointment of LuAnn Via as Chairperson of the Board

Horsham, PA, December 20, 2017 — STRATA Skin Sciences, Inc. ("STRATA") (NASDAQ: SSKN), today announced that effective immediately LuAnn Via, current Board member and Chair of the Compensation Committee of the Board, has been unanimously appointed as Chairperson of the Board. The Board made the appointment after Jeffrey O'Donnell, Sr. informed the Board that, because of the growing needs of his other commitments, he could no longer devote the time and energy as required by the position of Chairman, but that he would continue to serve as a Board member.

Mr. O'Donnell stated, "I and the entire STRATA Board have been so impressed with LuAnn's leadership and experience. Her skill sets will be invaluable as STRATA seeks to enhance its position in the therapeutic and aesthetic dermatology market. I look forward to collaborating with LuAnn, as well as the entire STRATA Board and management team, as we seek to build value for all of our stockholders."

"STRATA Skin Sciences has made significant progress in developing its products and expanding its product offerings," said Ms. Via. "I am delighted to assume the role of Chairperson and look forward to working with the team in its continuing efforts to develop, commercialize and market innovative products for the treatment of dermatologic conditions. On behalf of the STRATA Board, I want to thank Jeff O'Donnell for his longstanding service as our Chairman."

About STRATA Skin Sciences, Inc. ([www.strataskin.com](http://www.strataskin.com))

STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; the STRATAPEN™ MicroSystem, marketed specifically for the intended use of micropigmentation; and Nordlys, a multi-technology aesthetic laser device.

### Trademarks

Ellipse and Nordlys are trademarks of Ellipse S/A, Horsholm, Denmark.

### Safe Harbor

*This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company's plans, objectives, expectations and intentions and may contain words such as "will," "may," "seeks," and "expects," that suggest future events or trends. These statements, including the development of the Company's products and additional product offerings, the Company's ability to enhance its position in the therapeutic and aesthetic dermatology market, are based on the Company's current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company's expectations due to financial, economic, business, competitive, market, regulatory and political factors or*

*conditions affecting the Company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the Company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. The Company assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at [www.sec.gov](http://www.sec.gov) and [www.strataskin.com](http://www.strataskin.com).*

**Investor Contacts:**

Frank McCaney, Chief Executive Officer  
STRATA Skin Sciences, Inc.  
215-619-3200  
[fmccaney@strataskin.com](mailto:fmccaney@strataskin.com)

Bob Yedid, Managing Director  
LifeSci Advisors, LLC  
646-597-6989  
[Bob@LifeSciAdvisors.com](mailto:Bob@LifeSciAdvisors.com)